Are Natalizumab and Fingolimod Analogous Second-Line Options for the Treatment of Relapsing-Remitting Multiple Sclerosis? A Clinical Practice Observational Study. Gajofatto A, Bianchi M R, Deotto L, Benedetti M D Eur Neurol. 2014 Sep 6; 72(3-4):173-180. Epub 2014 Sep 06. PMID: 25226868. Abstract CommentRecommendBookmarkWatch